No of your stocks has realtime/relevant news articles that can be accessed.
Take a look into our News feed to read about recent price changes and analysis.
Sentiment statistics ?
Please use our Financial history templates to chart, read and compare all 10'Q filings in depth.
|Market Cap||149.0 million|
|Outstanding Shares||49.8 million|
|Sector Name||Health Care|
|Country Short Name||FR|
|Announcement Earnings||2023-11-09 10:59:00+00:00|
There is no dividend data to display. Refer our Dividend calendar for other accurate data.
Please sign up and become a member to view all risk profiles.
Use our 'Focus' approach as text-and chart based summaries of the financial standing for a company. They are solely focussing on the company's market, risks and chances.
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA);